2023
Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchMeSH KeywordsBayes TheoremBuprenorphineCOVID-19Cross-Sectional StudiesHumansOpioid-Related DisordersPandemicsConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger studyBuilding medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods
Molfenter T, Jacobson N, Kim J, Horst J, Kim H, Madden L, Brown R, Haram E, Knudsen H. Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods. Journal Of Substance Use And Addiction Treatment 2023, 147: 208975. PMID: 36804353, PMCID: PMC10833474, DOI: 10.1016/j.josat.2023.208975.Peer-Reviewed Original ResearchConceptsRecruitment strategiesAdvanced nurse practitionersSUD treatment servicesSUD clinicsPhysician prescribersOpioid epidemicPhysician recruitmentNurse practitionersTreatment servicesPhysician assistantsPatient carePrescribing capacityPrescribersStudy settingClinical resourcesDisorder settingsStudy periodPhysiciansTreatment sitesYear 3Dedicated budgetIndividual factorsBuprenorphineMedicationsClinic
2022
Enhancing Use of Medications for Opioid Use Disorder Through External Coaching
Molfenter T, Kim H, Kim JS, Kisicki A, Knudsen HK, Horst J, Brown R, Madden LM, Toy A, Haram E, Jacobson N. Enhancing Use of Medications for Opioid Use Disorder Through External Coaching. Psychiatric Services 2022, 74: 265-271. PMID: 36196533, PMCID: PMC10836327, DOI: 10.1176/appi.ps.202100675.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNaltrexoneOhioOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid use disorderBuprenorphine useControl armUse disordersUse of MOUDUse of medicationsInjectable naltrexoneNaltrexone administrationOutcome measuresCoaching armClinical sitesHealth systemProvider UtilizationTrial periodTreatment agenciesTrialsDelivery modalitiesHealth sitesMedicationsSignificant differencesDisordersArmSimilar patternMOUDNaltrexone
2021
Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine
Du CX, Shi J, Tetrault JM, Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family Practice 2021, 39: 234-240. PMID: 34893825, PMCID: PMC8947790, DOI: 10.1093/fampra/cmab166.Peer-Reviewed Original ResearchConceptsOffice-based opioid treatmentPrimary care providersOpioid use disorderUrine toxicologyOpioid treatmentMore primary care providersOutpatient primary care clinicsChronic pain statusChronic viral hepatitisPrimary care clinicsCommon comorbid conditionsPrimary care characteristicsAddiction treatment settingsHigher median numberEvidence-based treatment modelsOBOT patientsOBOT programOlder patientsPain statusViral hepatitisCommon medicationsRetrospective reviewCare clinicsChronic painComorbid conditionsPrescribers’ satisfaction with delivering medications for opioid use disorder
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Kim H, Madden LM, Haram E, Molfenter T. Prescribers’ satisfaction with delivering medications for opioid use disorder. Substance Abuse Treatment, Prevention, And Policy 2021, 16: 78. PMID: 34663379, PMCID: PMC8521499, DOI: 10.1186/s13011-021-00413-7.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPersonal SatisfactionConceptsType of MOUDOpioid use disorderPrescriber satisfactionPrescriber characteristicsUse disordersXR-naltrexoneBuprenorphine treatmentExtended-release naltrexoneUS opioid epidemicOverall satisfactionRelease naltrexoneGreater overall satisfactionClinical trialsOpioid epidemicMethodsAs partMOUDWeb-based surveyPatient censusPrescribersMedicationsBuprenorphineDisordersTreatmentCurrent studyHigh levels
2020
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal Of Substance Use And Addiction Treatment 2020, 121: 108164. PMID: 33191004, PMCID: PMC7769928, DOI: 10.1016/j.jsat.2020.108164.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyTake-home dosingInterim guidanceShort-term overall mortalityOpioid agonist treatment programPerson clinical encountersOAT deliveryAgonist therapyOverall mortalityCOVID-19 transmissionPatient dropoutOAT patientsNaloxone distributionOverdose educationClinical practiceClinic interactionsTreatment programClinical encountersPatientsCliniciansCOVID-19COVID-19 pandemicOverdosesDosingPrevious yearThe real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatmentOrganizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use
Jacobson N, Horst J, Wilcox-Warren L, Toy A, Knudsen HK, Brown R, Haram E, Madden L, Molfenter T. Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use. The Journal Of Behavioral Health Services & Research 2020, 47: 439-448. PMID: 32347426, PMCID: PMC7578054, DOI: 10.1007/s11414-020-09706-4.Peer-Reviewed Original Research
2019
Physicians’ satisfaction with providing buprenorphine treatment
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Collier E, Starr S, Madden LM, Haram E, Toy A, Molfenter T. Physicians’ satisfaction with providing buprenorphine treatment. Addiction Science & Clinical Practice 2019, 14: 34. PMID: 31446893, PMCID: PMC6709557, DOI: 10.1186/s13722-019-0163-3.Peer-Reviewed Original ResearchConceptsBuprenorphine treatmentBaseline Web-based surveyOpioid use disorderGeneral medical practiceStudy of physiciansMedical practiceWaivered physiciansTreatment recommendationsClinical trialsRisk factorsOpioid epidemicImportant treatmentMethodsAs partUse disordersWeb-based surveyPhysician job satisfactionPhysiciansTreatment organizationsBuprenorphineSignificant differencesTreatmentOverall satisfactionSatisfaction itemsStudy measuresLower satisfactionElectronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment
Baldassarri SR, Fiellin DA, Savage ME, Madden LM, Beitel M, Dhingra LK, Fucito L, Camenga D, Bollampally P, Barry DT. Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment. Drug And Alcohol Dependence 2019, 197: 37-41. PMID: 30769264, PMCID: PMC6637405, DOI: 10.1016/j.drugalcdep.2018.12.012.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyCurrent cigarette smokingCigarette smokingEC useHigher oddsFormer smokersLower oddsPsychiatric distressPast cigarette smokingElectronic cigarette useAgonist therapyCurrent smokersBuprenorphine treatmentChronic painTobacco useNicotine dependenceUse disordersSmokingCigarette useMultivariate analysisElectronic cigarettesSmokersCigarettesMultivariate model
2018
Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S, Dvoriak S, Altice FL. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 87: 1-8. PMID: 29471921, PMCID: PMC5826566, DOI: 10.1016/j.jsat.2018.01.007.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMethadone maintenance treatmentConcurrent illicit drug useOAT patientsIllicit drug useDrug injectionDrug useAgonist treatmentUse disordersMultivariable logistic regressionConcurrent drug useOngoing drug usePolysubstance use disorderAlcohol use disorderMaintenance treatmentIndependent correlatesBMT programSevere opioidDrug injectingPatientsHealth outcomesTreatment dropoutAlcohol dependenceInjection initiationYounger age
2017
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial
Molfenter T, Knudsen HK, Brown R, Jacobson N, Horst J, Van Etten M, Kim JS, Haram E, Collier E, Starr S, Toy A, Madden L. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implementation Science 2017, 12: 135. PMID: 29141653, PMCID: PMC5688699, DOI: 10.1186/s13012-017-0665-x.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction treatment fieldPrevalence of OUDSubstantial public health significanceOpioid misuse epidemicExtended-release naltrexonePrimary treatment outcomeEvidence-based pharmacotherapyAddiction treatment workforceSignificant health issuePublic health significanceAddiction treatment providersNaltrexone patientsNon-medical useOUD pharmacotherapyTreatment fieldOUD patientsBuprenorphine patientsPrescription opioidsCluster RCTIntervention periodTreatment outcomesImplementation interventionsOverdose deathsUse disordersUsing nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine
Madden L, Bojko MJ, Farnum S, Mazhnaya A, Fomenko T, Marcus R, Barry D, Ivanchuk I, Kolomiets V, Filippovych S, Dvoryak S, Altice FL. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine. International Journal Of Drug Policy 2017, 49: 48-53. PMID: 28957756, DOI: 10.1016/j.drugpo.2017.07.025.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNominal group techniqueAgonist therapyBuprenorphine maintenance treatmentAddiction treatment approachesImplementation science strategiesOAT servicesMaintenance treatmentClinical providersTreatment approachesTreatment servicesNGT discussionRegional controlTherapyCliniciansGroup techniqueStructural barriers